Figure 1 (Rituxan 01)
Rituxan Injection, Solution
Product Images NDC 50242-053
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rituxan (NDC 50242-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Rituxan 02)
This text represents a graph or a chart that shows the percentage of ACR 20 Responders after receiving either a placebo or a 2x1000mg dose of Rituxan at different time points (from 0 to 24 weeks).*
Figure 3 (Rituxan 03)
Principal Display Panel (100 mg Vial Carton)
This is a product information for Rituxan® (rituximab) Injection, which is identified by NDC 50242-051-21. It comes in a 100 mg/10mL (10 mg/mL) vial for intravenous use. The product is marked with an "R" indicating it is available only by prescription.*
Principal Display Panel (500 mg Vial Carton)
This is a medication called Rituxan® (rituximab) which is available in injection form as a 500mg/50mL solution for intravenous use. It is jointly marketed by Biogen and Genentech USA, Inc. The National Drug Code (NDC) assigned to this medication is 50242-053-06.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
